베타
임상 레이더 AI
임상시험 NCT07148388 (AiTBS)은(는) Neuropathic Pain, Nociceptive Pain에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰

Accelerated Intermittent Theta Burst Stimulation (AiTBS)on Neuropathic Pain 120

모집중
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07148388 (AiTBS)은(는) Neuropathic Pain, Nociceptive Pain에 대해 알아보는 중재연구입니다. 현재 상태는 모집중이며, 연구는 2025년 9월 12일에 시작되어 120명의 참여자를 모집하고 있습니다. Second Affiliated Hospital, School of Medicine, Zhejiang University이(가) 진행하며, 2027년 12월 31일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 1월 26일에 갱신되었습니다.
간단한 개요
The present study was designed to be the first to evaluate the efficacy of the AiTBS protocol to relieve neuropathic pain in a therapeutic setting, i.e. with repeated stimulation sessions. The investigator directly compared the analgesic efficacy of AiTBS versus conventional 10-Hz rTMS delivered to the left M1. In addition to pain experiences, The investigator examined the effects of intervention on corticospinal exc...더 보기
공식 제목

Effects and Mechanism of Accelerated Intermittent Theta Burst Stimulation on Neuropathic Pain

질환명
Neuropathic Pain, Nociceptive Pain
기타 연구 식별자
  • AiTBS
  • 2024-0669
NCT 번호
실제 연구 시작일
2025-09-12
최신 업데이트 게시
2026-01-26
예상 연구 완료일
2027-12-31
계획된 등록 인원
120
연구종류
중재연구
단계/상
해당 없음
상태
모집중
키워드
AiTBS, rTMS, Neuropathic pain
주요 목적
치료
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
삼중맹검
시험군 / 개입
참가자 그룹/시험군개입/치료
실험적AiTBS group
Eligible patients were receive 5 days of AiTBS on left M1 within 10 days. Clinical and neurophysiological assessments were performed at baseline and after the last sessions.
반복적 경두개 자기 자극
Patients in the AiTBS group received 5 consecutive days of AiTBS treatment, with 6 sessions of iTBS interventions per day (1800 pulses per trial, with a 50-minute interval between trials). Patients in the 10Hz rTMS group received 10 consecutive days of 10Hz rTMS treatment within 10 days, with 1500 pulses per day, totaling 15 minutes.
활성 대조군10Hz rTMS
Patients were assigned to receive 10 consecutive days of classic 10Hz rTMS intervention on left M1. Clinical and neurophysiological assessments were performed at baseline and after the last sessions.
반복적 경두개 자기 자극
Patients in the AiTBS group received 5 consecutive days of AiTBS treatment, with 6 sessions of iTBS interventions per day (1800 pulses per trial, with a 50-minute interval between trials). Patients in the 10Hz rTMS group received 10 consecutive days of 10Hz rTMS treatment within 10 days, with 1500 pulses per day, totaling 15 minutes.
주요결과변수
결과변수측정값 설명시간 범위
Visual analogue scale
It typically consists of a 10-centimeter straight line, with two endpoints representing extreme states of the measured experience. For example, when assessing pain, one end is labeled "0 (no pain at all)" and the other end "10 (worst pain imaginable, unbearable)". The individual being evaluated marks a point on the line that corresponds to their current experience. The score is determined by measuring the distance from this mark to the "0" end, converted into a numerical value ranging from 0 to 10 (where each centimeter equals 1 point). Higher scores indicate a stronger intensity of the experience.
Day1(Baseline), day 5 in AiTBS group, day 10 in 10Hz group, 1 month after intervention
이차결과변수
결과변수측정값 설명시간 범위
short-form McGill Pain Questionnaire (SF-MPQ)
The Short-Form McGill Pain Questionnaire (SF-MPQ) is a concise, widely used tool designed to assess the nature and intensity of pain in a efficient manner. Key Components: * Sensory pain descriptors (11 items): These words capture the physical qualities of pain, such as "throbbing," "burning," "aching," and "sharp." Respondents rate each on a scale of 0 (none) to 3 (severe). * Affective pain descriptors (4 items): These reflect the emotional aspects of pain, including "tiring," "fearful," "punishing/cruel," and "worrying." They are also rated 0-3. * Visual Analog Scale (VAS): A 10-centimeter line with endpoints labeled "no pain" and "worst imaginable pain." Patients mark a point along the line to indicate their pain intensity. * Present Pain Intensity (PPI): A 6-point scale (0-5) ranging from "no pain" (0) to "excruciating" (5), used to rate the current level of pain.
Day1(Baseline), day 5 in AiTBS group, day 10 in 10Hz group, 1 month after intervention
7-item pain interference scale of the Brief Pain Inventory (BPI)
* Items assessed: The 7 items evaluate how pain interferes with: * General activity * Mood * Walking ability * Normal work (including both work outside the home and housework) * Relationships with others * Sleep * Enjoyment of life * Rating scale: Each item is rated on an 11-point numerical scale (0 = "does not interfere" to 10 = "interferes completely"), based on the past 24 hours.
Day1(Baseline), day 5 in AiTBS group, day 10 in 10Hz group, 1 month after intervention
The Patient Global Impression of Change (PGIC)
* Single-item structure: It consists of a single question that asks patients to rate how much their condition has changed since a specified baseline (e.g., "Since starting treatment, how would you rate your overall change in pain?"). * 7-point response scale: Responses range from "very much improved" (score 1) to "very much worse" (score 7), with intermediate options including "much improved," "minimally improved," "no change," "minimally worse," and "much worse." * Subjective and holistic: It captures the patient's personal, global judgment rather than focusing on specific symptoms, reflecting their integrated experience of change.
Day1(Baseline), day 5 in AiTBS group, day 10 in 10Hz group, 1 month after intervention
The 17-item Hamilton Depression Rating Scale (HAMD-17)
It includes 17 items covering core depressive symptoms and related manifestations, mainly involving the following dimensions: * Emotional symptoms: Such as depressed mood, feelings of guilt, suicidal ideation, etc. * Somatic symptoms: Including difficulty falling asleep, difficulty maintaining sleep, early awakening, reduced work and interests, retardation (psychomotor), agitation (psychomotor), somatic anxiety, gastrointestinal symptoms, general symptoms, sexual symptoms, etc. * Other related symptoms: Such as weight loss, insight, delusional or obsessive symptoms, depersonalization or derealization, paranoid symptoms, compulsive symptoms, etc. (Some items vary slightly according to versions, with the core being emotional and somatic manifestations related to depression).
Day1(Baseline), day 5 in AiTBS group, day 10 in 10Hz group, 1 month after intervention
The Beck Depression Inventory-II (BDI-II)
The Beck Depression Inventory-II (BDI-II) is a widely used self-report questionnaire designed to assess the severity of depressive symptoms in adults and adolescents. It consists of 21 items, each describing a specific depressive symptom (e.g., sadness, loss of interest, guilt, fatigue, sleep disturbances, appetite changes).
Day1(Baseline), day 5 in AiTBS group, day 10 in 10Hz group, 1 month after intervention
TMS-EEG
TMS-EEG (Transcranial Magnetic Stimulation-Electroencephalography) is a combined neuroimaging technique that synchronously uses TMS to non-invasively stimulate specific brain regions and EEG to record the brain's electrical activity responses to this stimulation.
Day1(Baseline), day 5 in AiTBS group, day 10 in 10Hz group
참여 도우미
적격성 기준

연령대
성인, 노인
최소 연령
18 Years
참여 가능한 성별
전체
  • IASP diagnosis of peripheral neuropathic pain;
  • At least three months after the onset of pain;
  • At least moderate pain intensity (≥ 3 assessed by VAS or NRS);
  • 18 years or older;
  • Stable medical treatment from 2 weeks before allocation to the end of the trial;
  • Willing to receive TMS treatment and capable of fulfilling clinical assessments.

  • Contradictions to TMS treatment, such as metal implants or seizure;
  • Serious psychiatric disorder (Hamilton Depression Rating Scale score ≥ 35 or Hamilton Anxiety Rating Scale score ≥ 29);
  • Aphasia or cognitive disorders (Mini mental state examination ≤ 24);
  • Severe clinical disorders caused by tumor or other conditions;
  • Severe cardiopulmonary dysfunction or extreme weakness;
  • History of substance abuse (alcohol, drugs).
Second Affiliated Hospital, School of Medicine, Zhejiang University logoSecond Affiliated Hospital, School of Medicine, Zhejiang University
연구 책임자
Min Yan, 책임연구자, prof., Second Affiliated Hospital, School of Medicine, Zhejiang University
연구 대표 연락처
연락처: Ying Liu, 86-15595512306, [email protected]
1 1개국에 임상시험 장소
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Ying Liu, 연락처, 15595512306, [email protected]
모집중